Marinus Pharma (MRNS) Plans Public Offering of Common Stock and Concurrent Private Placement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Marinus Pharma (MRNS) Announces Elan Ezickson to Board
December 12, 2019 7:31 AM ESTMarinus Pharmaceuticals, Inc. (NASDAQ: MRNS) announced today that Elan Ezickson, has joined the Companys Board of Directors. Mr. Ezickson is a highly accomplished executive with over 30 years of experience in the life sciences industry across commercial, operational and strategic... More
Marinus Pharma (MRNS) Prices 28M Share Common Offering at $1.25/Sh; Announces Concurrent Private Placement
December 11, 2019 9:15 AM ESTMarinus Pharmaceuticals, Inc. (NASDAQ: MRNS) today announced the pricing of an underwritten public offering of 28,000,000 shares of common stock at a public offering price of $1.25 per share. The gross proceeds to the Company from the public offering and concurrent private placement are expected to be approximately $65 million before deducting underwriting discounts and commissions, placement agent fees, and other estimated offering expenses. The Company has granted to the underwriters... More



